SCHEMBL437937

SCHEMBL437937

CO[C@H]1/C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(OCC(=O)O)c4c3C2=O)NC(=O)/C(C)=C\C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 5/20 0.84
TBXA2R P21731 3/20 0.84
CHRM1 P11229 3/20 0.84
PTGS1 P23219 3/20 0.84
SLCO2B1 O94956 2/20 0.84
ADRA1A P35348 2/20 0.84
SLCO1A2 P46721 2/20 0.84
SLCO1B3 Q9NPD5 2/20 0.84
SLCO1B1 Q9Y6L6 2/20 0.84
MAPT P10636 4/20 0.67
ABCC4 O15439 4/20 0.67
ABCC2 Q92887 4/20 0.67
GAA P10253 3/20 0.67
MAPK1 P28482 3/20 0.67
ABCC3 O15438 3/20 0.67
NR1I2 O75469 2/20 0.67
ADRB2 P07550 2/20 0.67
ADRB1 P08588 2/20 0.67
ADORA3 P0DMS8 2/20 0.67
ADRA2B P18089 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL437936 1.00 ABCB11 (0.84) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
SCHEMBL22553370 1.00 ABCB11 (0.84) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
SCHEMBL16509411 1.00 ABCB11 (0.84) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
SCHEMBL18573042 1.00 ABCB11 (0.84) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
SCHEMBL30825668 1.00 ABCB11 (0.84) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
SCHEMBL31171049 1.00 ABCB11 (0.84) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
SCHEMBL16509382 0.94 ABCB11 (0.74) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
Rifamide SCHEMBL1650471 0.93 ABCB11 (0.80) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
Rifamide SCHEMBL49237 0.93 ABCB11 (0.80) ABCB11TBXA2RCHRM1PTGS1SLCO2B1
Rifamide SCHEMBL49236 0.93 ABCB11 (0.80) ABCB11TBXA2RCHRM1PTGS1SLCO2B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102392-A1 PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES MEDILABO RFP INC (JP) 2026-04-16 US claimed
US-12521387-B2 Prophylactic or therapeutic drug for neurodegenerative diseases MEDILABO RFP, INC. (JP) 2026-01-13 US claimed
CN-120079435-A Iron single-atom catalyst for high-efficiency directional conversion of rifamycin B to O and application thereof 浙江大学 2025-06-03 CN claimed
CN-119023845-A HPLC method for rapidly and simultaneously separating and measuring rifamycin SV, rifamycin S and rifamycin B in fermentation broth 神舟生物科技有限责任公司 2024-11-26 CN claimed
EP-4438039-A2 ORAL RIFAMYCIN SV COMPOSITIONS Cosmo Technologies Ltd. (IE) 2024-10-02 EP claimed
EP-3706724-B1 ORAL RIFAMYCIN SV COMPOSITIONS COSMO TECHNOLOGIES LTD (IE) 2024-09-11 EP claimed
US-20240139178-A1 METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION AMYLOID SOLUTION INC. (KR) 2024-05-02 US claimed
CN-117447486-A Preparation method of rifaximin intermediate rifamycin O 扬州市三药制药有限公司 2024-01-26 CN claimed
CN-117230131-A Fermentation method and fermentation medium of rifamycin 浙江昌海制药有限公司 2023-12-15 CN claimed
EP-3650024-B1 PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION COMPRISING RIFAMPICINS FOR TREATING DEMENTIA MEDILABO RFP INC (JP) 2023-10-25 EP claimed
EP-0980438-A1 BETAINES AS ADJUDVANTS TO SUSCEPTIBILITY TESTING AND ANTIMICROBIAL THERAPY Integrated Research Technology, LLC (US) 2000-02-23 EP claimed
US-5985560-A INSERTION PLASMID INTO DNA LAL RUP (IN) 1999-11-16 US claimed
WO-1998050576-A1 BETAINES AS ADJUVANTS TO SUSCEPTIBILITY TESTING AND ANTIMICROBIAL THERAPY INTEGRATED RESEARCH TECHNOLOGY, LLC (US) 1998-11-12 WO claimed
EP-0877087-A1 Cloning vectors for Amycolatopsis sp. and a process for the preparation thereof The Secretary, Department of Biotechnology (IN) 1998-11-11 EP claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
US-4431735-A FERMENTATION OF HUMICOLA OR MONOCILLIUM KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1984-02-14 US claimed
US-4409209-A POTENTIATION OF ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1983-10-11 US claimed
US-4402877-A DESORPTION THE DOW CHEMICAL COMPANY (US) 1983-09-06 US claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-4267274-A AND NUTRIENT MEDIUM CONTAINING A CARBON SOURCE, A NITROGEN SOURCE AND MINERAL SALTS GRUPPO LEPETIT S.P.A. (IT) 1981-05-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139178-A1 METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION PSEN2, PSEN1, NEFM ABCB11 4667/4885TBXA2R 4353/4885CHRM1 399/4885
US-20260102392-A1 PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES MAPT, SNCA, FUS ABCB11 488/4885TBXA2R 4680/4885CHRM1 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.